Merck Canada said it has successfully completed negotiations on its PAH therapy Winrevair with the pan‑Canadian Pharmaceutical Alliance.

Merck plans a Phase 3 trial of Winrevair after a Phase 2 study testing it in CpcPH due to HFpEF hit its main goal.

Columnist Anna Jeter writes that, despite any setbacks, people with pulmonary hypertension should continue to take charge of their care.

Low oxygen levels, or hypoxia, in early life impaired lung blood vessel growth, leading to severe pulmonary hypertension in a ...

Pulmonary hypertension (PH) is a rare, chronic, progressive disease characterized by high blood pressure in the blood vessels of the lungs, known as the pulmonary arteries. The World Health ...